• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Annual Information Update

    April 2, 2012

    Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2011 and March 31, 2012 (save for the final item under section 3 below which has been deemed as having been filed on March 31, 2011).

    The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date.  The information appears by way of record and the Company is under no obligation to update it.

    1. Announcements made via a RIS

    The documents listed below were published via a Regulatory Information Service on or around the dates indicated.

    30-Mar-12    Shire Announces Top-line Results of the PREVENT2 Trial

    22-Mar-12    2011 Annual Report - DTR 6.3.5 Disclosure

    15-Mar-12    Shire to acquire FerroKin BioSciences, Inc.

    15-Mar-12    Shire Update on US BLA Filing for REPLAGAL®

    06-Mar-12    PDMR Share Dealing

    01-Mar-12    Total Voting Rights

    01-Mar-12    Elections for Interim Dividend

    29-Feb-12    Director/PDMR Share Dealings

    28-Feb-12    PDMR Share Dealing

    27-Feb-12    Director Declaration

    24-Feb-12    PDMR Share Dealings

    23-Feb-12    PDMR Share Dealings

    22-Feb-12    Director/PDMR Share Dealings

    09-Feb-12    Another strong year for Shire

    01-Feb-12    Total Voting Rights

    31-Jan-12    Full Year 2011 results date notification - Feb 9, 2012

    23-Jan-12    Holding(s) in Company

    05-Jan-12    VENVANSE Marketing Application accepted for review in EU

    03-Jan-12    Total Voting Rights

    30-Dec-11    Director/PDMR Shareholding

    15-Dec-11    Shire plc Board and Committee Changes

    14-Dec-11    Director/PDMR Shareholding

    12-Dec-11    Director/PDMR Shareholding

    01-Dec-11    Total Voting Rights

    01-Dec-11    Director/PDMR Shareholding

    24-Nov-11    Block listing six monthly return

    21-Nov-11    Director/PDMR Shareholding

    07-Nov-11    Director/PDMR Shareholding

    02-Nov-11    PDMR Share Transactions

    01-Nov-11    Total Voting Rights

    01-Nov-11    Director Declaration

    28-Oct-11    Continued strong product sales performance in Q3

    13-Oct-11    3rd Quarter Results Notification

    03-Oct-11    Total Voting Rights

    30-Sep-11    Director/PDMR Shareholding

    26-Sep-11    Director/PDMR Shareholding

    01-Sep-11    Elections for Interim Dividend

    01-Sep-11    Total Voting Rights

    25-Aug-11    Regulatory Approval

    12-Aug-11    Purchase of Shares by Employee Benefit Trust

    11-Aug-11    Half Yearly Report

    03-Aug-11    Director/PDMR Shareholding

    02-Aug-11    Director/PDMR Shareholding

    01-Aug-11    Director/PDMR Shareholding

    01-Aug-11    Total Voting Rights

    29-Jul-11    Holding(s) in Company

    28-Jul-11    Shire’s quarterly revenues grow by 25%

    27-Jul-11    Board Changes

    15-Jul-11    Second quarter 2011 results date notification

    07-Jul-11    Shire files lawsuit against Watson and Roxane

    01-Jul-11    Shire files lawsuit against Sandoz and Amneal

    01-Jul-11    Total Voting Rights

    28-Jun-11    Shire completes acquisition of Advanced BioHealing, Inc.

    24-Jun-11    Purchase of Shares by Employee Benefit Trust

    21-Jun-11    Director/PDMR Shareholding

    17-Jun-11    Director/PDMR Shareholding

    01-Jun-11    Total Voting Rights

    25-May-11    Shire receives VYVANSE(R) Paragraph IV Notice Letters

    24-May-11    Block listing - Six Monthly Return

    19-May-11    Shire receives VYVANSE(R) Paragraph IV Notice Letter

    18-May-11    Shire to acquire Advanced BioHealing

    09-May-11    Director/PDMR Shareholding

    06-May-11    Purchase of Shares by Employee Benefit Trust

    04-May-11    Director Declaration

    03-May-11    Total Voting Rights

    28-Apr-11    Shire delivers a strong first quarter performance

    26-Apr-11    Result of AGM

    20-Apr-11    Notice of Results

    19-Apr-11    Holding(s) in Company

    06-Apr-11    Shire files lawsuit against Watson Pharmaceuticals

    01-Apr-11    Director/PDMR Shareholding

    01-Apr-11    Total Voting Rights

    01-Apr-11    Annual Information Update

    2. Documents filed with the Securities and Exchange Commission (“SEC”)

    The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ.  Full details of these filings can be found on the SEC’s website at www.sec.gov.

    3. Documents filed with Companies Registry, Jersey

    Date of Delivery Document
    24-Feb-12 Annual Return
    17-May-11 Special Resolutions passed on April 26, 2011
    31-Mar-11 Annual Report and Accounts for the year ended December 31, 2010


    4. Documents sent to Shareholders

    The following documents were published and sent to shareholders, and are available on the Company’s website.

    Date of Delivery Document
    22-Mar-12 Annual Report and Accounts for the year ended December 31, 2011
    22-Mar-12 Notice of 2012 Annual General Meeting

    A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.

    Tony Guthrie

    Deputy Company Secretary


    For further information please contact:

    Investor Relations    
    Eric Rojas    erojas@shire.com +1 781 482 0999
    Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157



    Notes to editors


    Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

    For further information on Shire, please visit the Company’s website: www.shire.com.